← ConditionsAutoimmune & chronic complex illness

Chronic fatigue / burnout

Bioenergetic failure with immune & HPA overlap; restore mitochondrial output.

Decision support, not prescription. You decide.

Primary: Cellular Energy, Mito & LongevitySecondary: Immune & Inflammation ModulationSecondary: Hormonal Optimization & HPTA SupportSummary grade: preclinical
!

WarningBPC-157 crash risk in post-viral/ME-CFS

Post-viral/ME-CFS patients report crashing at standard dose; microdose 10–25%.

Candidate agents

5 agents · ranked by role, then evidence
NAD+peptide · headlineLead503A compounded
Evidence · PubMed
Emerging

In CFS, oral NADH combined with CoQ10 reduced perceived fatigue and fatigue-impact scores in two small 8-week RCTs, and raised intracellular NAD+/NADH and ATP; evidence is for the NADH+CoQ10 combination, not NAD+ monotherapy.

PMID 25386668
Community · Reddit
No community reports
Peers · your network
No peer data yet
Elamipretidepeptide · headlineResearch use only
Evidence · PubMed
Strong

In the phase 3 MMPOWER-3 RCT in primary mitochondrial myopathy, subcutaneous elamipretide did NOT improve total fatigue score or 6-minute walk distance vs placebo (Class I evidence), though it was well tolerated.

PMID 37268435
Community · Reddit
No community reports
Peers · your network
No peer data yet
MOTS-cpeptide · headline503A · PCAC-pending
Evidence · PubMed
Preclinical

MOTS-c, a 16-aa mitochondrial-derived peptide, activates AMPK in skeletal muscle and improved insulin sensitivity and metabolic homeostasis in mice; proposed as an exercise mimetic, but evidence in fatigue/burnout is entirely preclinical.

PMID 25738459
Community · Reddit
No community reports
Peers · your network
No peer data yet
Humaninpeptide · headlineResearch use only
Evidence · PubMed
None

Humanin is a mitochondrial-derived cytoprotective peptide of interest for bioenergetic decline, but there is no direct human or animal literature evaluating it in chronic fatigue or burnout; listed as a mechanistic gap, not an evidence-backed option.

Community · Reddit
No community reports
Peers · your network
No peer data yet
Low-Dose Naltrexoneoff-label Rx · co-headlineFDA-approved · off-label
Evidence · PubMed
Anecdotal

Low-dose naltrexone (typically 4.5 mg/day) has reported symptom benefit in a small ME/CFS case series and in related fibromyalgia/post-COVID fatigue, with a favorable safety profile; a phase II RCT for post-COVID fatigue is underway but confirmatory controlled efficacy data are lacking (evidence to date is case-series/anecdotal plus an unfinished protocol).

PMID 31911410
Community · Reddit
No community reports
Peers · your network
No peer data yet

Matching protocol templates

Browse all →

The platform surfaces evidence, community signal and peer outcomes with enforced cautions. It never decides treatment — the licensed clinician orders labs, writes notes, and prescribes.